The results showed that the level of N-terminal pro-brain natriuretic peptide (NT-proBNP), a key biomarker used in HF diagnosis to reflect the severity of heart failure (10, 11), in patients with HFpEF was significantly lower in the treatment group than in the valsartan group after 12 weeks of treatment (12). This evidence concerns the gene NPPB and hydrops fetalis.